These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 1409715)

  • 1. Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator.
    Bevec D; Dobrovnik M; Hauber J; Böhnlein E
    Proc Natl Acad Sci U S A; 1992 Oct; 89(20):9870-4. PubMed ID: 1409715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutive expression of chimeric neo-Rev response element transcripts suppresses HIV-1 replication in human CD4+ T lymphocytes.
    Bevec D; Volc-Platzer B; Zimmermann K; Dobrovnik M; Hauber J; Veres G; Böhnlein E
    Hum Gene Ther; 1994 Feb; 5(2):193-201. PubMed ID: 8186299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.
    Lee SW; Gallardo HF; Gilboa E; Smith C
    J Virol; 1994 Dec; 68(12):8254-64. PubMed ID: 7966618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance.
    Liem SE; Ramezani A; Li X; Joshi S
    Hum Gene Ther; 1993 Oct; 4(5):625-34. PubMed ID: 8280800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.
    Plavec I; Agarwal M; Ho KE; Pineda M; Auten J; Baker J; Matsuzaki H; Escaich S; Bonyhadi M; Böhnlein E
    Gene Ther; 1997 Feb; 4(2):128-39. PubMed ID: 9081703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes.
    Bahner I; Zhou C; Yu XJ; Hao QL; Guatelli JC; Kohn DB
    J Virol; 1993 Jun; 67(6):3199-207. PubMed ID: 8388497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of trans-dominant mutants of the HIV type 1 Rev protein for their ability to inhibit Rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics.
    Ragheb JA; Bressler P; Daucher M; Chiang L; Chuah MK; VandenDriessche T; Morgan RA
    AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1343-53. PubMed ID: 8573391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and trans-dominant negative mutant Gag and Env proteins.
    Ding SF; Lombardi R; Nazari R; Joshi S
    Front Biosci; 2002 Feb; 7():a15-28. PubMed ID: 11815282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication.
    Malim MH; Freimuth WW; Liu J; Boyle TJ; Lyerly HK; Cullen BR; Nabel GJ
    J Exp Med; 1992 Oct; 176(4):1197-201. PubMed ID: 1402661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
    Peng H; Callison D; Li P; Burrell C
    Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes.
    Bauer G; Valdez P; Kearns K; Bahner I; Wen SF; Zaia JA; Kohn DB
    Blood; 1997 Apr; 89(7):2259-67. PubMed ID: 9116267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production and characterization of high-titer stocks of rev-defective HIV-1.
    Riggs NL; Guatelli JC
    Virology; 1996 Mar; 217(2):602-6. PubMed ID: 8610453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
    Mautino MR; Keiser N; Morgan RA
    J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells.
    Woffendin C; Yang ZY; Udaykumar ; Xu L; Yang NS; Sheehy MJ; Nabel GJ
    Proc Natl Acad Sci U S A; 1994 Nov; 91(24):11581-5. PubMed ID: 7972106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral potency of drug-gene therapy combinations against human immunodeficiency virus type 1.
    Junker U; Baker J; Kalfoglou CS; Veres G; Kaneshima H; Böhnlein E
    AIDS Res Hum Retroviruses; 1997 Nov; 13(16):1395-402. PubMed ID: 9359659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
    Mautino MR; Morgan RA
    Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication.
    Bonyhadi ML; Moss K; Voytovich A; Auten J; Kalfoglou C; Plavec I; Forestell S; Su L; Böhnlein E; Kaneshima H
    J Virol; 1997 Jun; 71(6):4707-16. PubMed ID: 9151864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture.
    Bahner I; Kearns K; Hao QL; Smogorzewska EM; Kohn DB
    J Virol; 1996 Jul; 70(7):4352-60. PubMed ID: 8676458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency.
    Pomerantz RJ; Seshamma T; Trono D
    J Virol; 1992 Mar; 66(3):1809-13. PubMed ID: 1738210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Rev-inducible mutant gag gene stably transferred into T lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 infection.
    Smythe JA; Sun D; Thomson M; Markham PD; Reitz MS; Gallo RC; Lisziewicz J
    Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3657-61. PubMed ID: 8170964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.